Streamlining your IVT workflow to maximize mRNA yields, from template design to synthesis
The recent pandemic highlighted the speed and flexibility of synthetic mRNA as a platform for vaccine development. These early successes paved the way for a revolutionary future of RNA-based therapies.
In this webinar, Dr. Tarik Hadi discusses Takara Bio’s unique end-to-end solution that generates ultra-high yields of synthetic mRNA with minimal time and reagents.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2023 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.